TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Kalbe to start COVID-19 vaccine trial with South Korean pharma firm

  • The Jakarta Post

Jakarta   /   Thu, June 4 2020   /  01:00 am
A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020. (REUTERS/Dado Ruvic/Illustration)

Publicly listed pharmaceutical company Kalbe Farma has signed an agreement with South Korea-based biotechnology firm Genexine Inc. to start a clinical trial of a COVID-19 candidate vaccine in Indonesia. Kalbe would also incorporate government agencies in the process to ensure public access to the vaccine once the trials showed positive results, the company’s president director Sie Djohan said. “We hope research and development on the COVID-19 vaccine can yield positive results to ensure vaccine access for Indonesia can be secured,” he said in a press statement on Thursday. The DNA vaccine prototype is being developed by a consortium of biotech companies and research institutions, namely Genexine, Binex, the International Vaccine Institute, GenNBio, the Korean Advanced Institute of Science and Technology and Pohang University of Science and Technology. The ca...